Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension

In an analysis of 404 patients with PV or ET, the use of renin-angiotensin inhibitors (RASi) demonstrated a protective effect from thrombotic-adverse events both in the cohort of patients with MPN and hypertension (HR 0.46; 95% CI: 0.21-0.98, p = 0.04) and in the subgroup of patients with thrombotic high-risk scores (HR 0.49; 95% CI: 0.24–1.01, p = 0.04). Data also showed that patients with ET and a high risk of thrombosis seem to benefit most from RASi treatment (HR 0.27; 95% CI: 0.07-1.01, p = 0.03).